Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 5, Mai 2011
Page(s) 514 - 520
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2011275017
Publié en ligne 25 mai 2011
  1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990 ; 61 : 759-767. [CrossRef] [PubMed] [Google Scholar]
  2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer : Molecular basis of colorectal cancer. N Engl J Med 2009 ; 361 : 2449-2460. [CrossRef] [PubMed] [Google Scholar]
  3. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005 ; 434 : 843-850. [CrossRef] [PubMed] [Google Scholar]
  4. Yang J, Zhang W, Evans PM, et al. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006 ; 281 : 17751-17757. [CrossRef] [PubMed] [Google Scholar]
  5. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007 ; 1773 : 1263-1284. [CrossRef] [PubMed] [Google Scholar]
  6. Bos JL, Fearon ER, Hamilton SR, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987 ; 327 : 293-297. [CrossRef] [PubMed] [Google Scholar]
  7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002 ; 417 : 949-954. [CrossRef] [PubMed] [Google Scholar]
  8. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation : a target for cancer chemotherapy. Leukemia 2003 ; 17 : 590-603. [CrossRef] [PubMed] [Google Scholar]
  9. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004 ; 304 : 554. [CrossRef] [PubMed] [Google Scholar]
  10. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer : mutations in a signalling pathway. Nature 2005 ; 436 : 792. [CrossRef] [PubMed] [Google Scholar]
  11. Xu Y, Pasche B.TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 2007 ; 16 n° special 1 : R14-R20. [CrossRef] [PubMed] [Google Scholar]
  12. Biswas S, Trobridge P, Romero-Gallo J, et al. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes Chromosomes Cancer 2008 ; 47 : 95-106. [CrossRef] [PubMed] [Google Scholar]
  13. Takagi Y, Kohmura H, Futamura M, et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 1996 ; 111 : 1369-1372. [CrossRef] [PubMed] [Google Scholar]
  14. Papazoglu C, Mills AA. p53 : at the crossroad between cancer and ageing. J Pathol 2007 ; 211 : 124-133. [CrossRef] [PubMed] [Google Scholar]
  15. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990 ; 249 : 912-915. [CrossRef] [PubMed] [Google Scholar]
  16. Hector S, Prehn JH. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer : a review. Biochim Biophys Acta 2009 ; 1795 : 117-129. [PubMed] [Google Scholar]
  17. Gnagnarella P, Gandini S, La Vecchia C, Maisonneuve P. Glycemic index, glycemic load, and cancer risk : a meta-analysis. Am J Clin Nutr 2008 ; 87 : 1793-1801. [PubMed] [Google Scholar]
  18. Key TJ, Spencer EA., Carbohydrates cancer : an overview of the epidemiological evidence.. Eur J Clin Nutr 2007 ; 61 : suppl 1S112-S121. [CrossRef] [PubMed] [Google Scholar]
  19. Pais R, Silaghi H, Silaghi AC, et al. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009 ; 15 : 5141-5148. [CrossRef] [PubMed] [Google Scholar]
  20. Yam D, Fink A, Mashiah A, Ben-Hur E. Hyperinsulinemia in colon, stomach and breast cancer patients. Cancer Lett 1996 ; 104 : 129-132. [CrossRef] [PubMed] [Google Scholar]
  21. Khaw KT, Wareham N, Bingham S, et al. Preliminary communication : glycated hemoglobin, diabetes, and incident colorectal cancer in men and women : a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 2004 ; 13 : 915-919. [PubMed] [Google Scholar]
  22. Giovannucci E. Insulin, insulin-like growth factors and colon cancer : a review of the evidence. J Nutr 2001 ; 131 : 3109S-3120S. [PubMed] [Google Scholar]
  23. Issad T. O-GlcNAc glycosylation and regulation of cell signaling. Med Sci (Paris) 2010 ; 26 : 753-759. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Yang X, Ongusaha PP, Miles PD, et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 2008 ; 451 : 964-969. [CrossRef] [PubMed] [Google Scholar]
  25. Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem 1995 ; 270 : 18961-18965. [CrossRef] [PubMed] [Google Scholar]
  26. Yang WH, Kim JE, Nam HW, et al. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 2006 ; 8 : 1074-1083. [CrossRef] [PubMed] [Google Scholar]
  27. Dehennaut V, Slomianny MC, Page A, et al. Identification of structural and functional O-linked N-acetylglucosamine-bearing proteins in Xenopus laevis oocyte. Mol Cell Proteomics 2008 ; 7 : 2229-2245. [CrossRef] [PubMed] [Google Scholar]
  28. Dehennaut V, Hanoulle X, Bodart JF, et al. Microinjection of recombinant O-GlcNAc transferase potentiates Xenopus oocytes M-phase entry. Biochem Biophys Res Commun 2008 ; 369 : 539-546. [CrossRef] [PubMed] [Google Scholar]
  29. Lefebvre T, Baert F, Bodart JF, et al. Modulation of O-GlcNAc glycosylation during Xenopus oocyte maturation. J Cell Biochem 2004 ; 93 : 999-1010. [CrossRef] [PubMed] [Google Scholar]
  30. Hatsell S, Medina L, Merola J, et al. Plakoglobin is O-glycosylated close to the N-terminal destruction box. J Biol Chem 2003 ; 278 : 37745-37752. [CrossRef] [PubMed] [Google Scholar]
  31. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009 ; 9 : 489-499. [CrossRef] [PubMed] [Google Scholar]
  32. Évaluation des risques et perspectives thérapeutiques en oncologie colorectale. Med Sci (Paris) 2009 ; 25 (hs1) : 1-56. [Google Scholar]
  33. Bodmer A, Goetsch L, Favet L, et al. Anticorps et tumeurs solides. Cibles établies et pistes prometteuse. Med Sci (Paris) 2009 ; 25 : 1090-1098. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.